Verdemed’s mission is to offer the best of approved existing and prospective cannabinoid products to all Latin Americans, in all countries, in all jurisdictions legally authorized to sell medical cannabis.
The company’s initial focus is on product formulations of cannabinoid pharmaceuticals currently available in Canada, Europe, and the USA. Verdemed aims to meet Latin America’s medical needs with similar products and medical cannabis treatments approved by Health Canada, EMA (European Medicines Agency), and the USA FDA (Food and Drug Administration).
Verdemed is uniquely positioned to tackle the high regulatory hurdles in Latin America with Canadian-derived pharmaceutical products.
Over the past 20 years, Canada has built a robust regulatory framework to protect patients’ safety and to secure reliable treatments with medical cannabis products. Most Latin American regulatory agencies have in place a regulatory regime similar to Canadian legislation around medical cannabis.
Verdemed leverages its Canadian DNA to offer high-end quality pharmaceuticals in Latin America.
José Bacellar is uniquely qualified to lead efforts across multiple jurisdictions, having assisted a number of North American companies to expand into Latin America. He brings extensive professional experience in the pharmaceutical industry and has relevant experience in the medical cannabis industry. Prior positions he has held include Head of Business Development for Canopy Latam; Interim COO at Canopy Health (UK); Head of Business Development at ACIC Pharmaceuticals (Canada); CEO at Vetnil (Brazil); and CEO & President at Bombril S/A (Brazil).